Aptevo’s AML Therapy Shows 86% Benefit, Secures $60 Million Equity Line
In 28 evaluable frontline AML patients, Aptevo’s mipletamig plus ven/aza delivered an 86% clinical benefit rate, including 79% CR/CRi and 61% complete remission, with zero cytokine release syndrome observed. Aptevo introduced three CD3 candidates with two trispecific assets and secured a $60 million equity line to support operations into 2029.
1. Clinical Progress of Mipletamig
Updated interim data from 28 evaluable frontline AML patients treated with mipletamig in triplet combination with venetoclax and azacitidine showed an 86% clinical benefit rate, including a 79% CR/CRi remission rate and 61% complete remission. Notably, no cytokine release syndrome was observed and 55% of remissions were MRD-negative, including 35% in high-risk TP53-mutant patients.
2. CD3 Platform Expansion
During 2025 Aptevo expanded its CD3 portfolio by adding three new multispecific candidates and introducing two trispecific assets leveraging its CRIS-7-derived CD3 binding domain. These additions broaden the ADAPTIR and ADAPTIR-FLEX platforms to target both hematologic and solid tumor indications, affirming the modularity of its immune-oncology pipeline.
3. Financial Results and Equity Line
Aptevo closed 2025 with $21.6 million in cash and cash equivalents versus $8.7 million at year-end 2024, funding $14.5 million in R&D and $11.8 million in G&A expenses. In 2026 the company established a $60 million equity line facility to extend its cash runway and support operations into 2029.
4. Leadership and Strategic Outlook
As Marvin White transitions to Executive Chair, Jeff Lamothe assumes the CEO role to drive execution of clinical programs and capital strategy. The leadership change underscores a focus on advancing mipletamig’s development, expanding multispecific candidates and leveraging financial flexibility to sustain growth.